Special Update: Performance Report
Editor’s note: Here are some of the leading biotech companies that have increased in price since Dr. Paul Ruggieri wrote about them in past Medical Technology Insight articles.
Earlier this month, Human Genome Sciences [HGSI>HGSI] reported finding an immune stimulator protein called the B lymphocute stimulator, from their genetic data bank. This discovery could have enormous implications in treating diseases like AIDS, cancer and in vaccine development. The stock soared 14 points on July 8 on this news, closing at 55, an all-time high. On Friday, July 9, it came back to earth some to close at just under 48, but by July 28 was trading back up at 52. When I originally wrote about HGSI, it was trading at 30.
Here is the performance of some related companies I have written about in past articles:
- Millennium Pharmaceuticals [MLNM>MLNM] was trading at 30 in February and was trading above 56 on July 28, 1999.
- Affymetrix [AFFX>AFFX] was at 38 when recommended in April and was trading above 69 on July 28 (it hit a 52-week high of 70 1/2 on July 9).
These two companies are leaders in the genomic field of drug research and all three rose a fair amount earlier in the month in response to the HGSI news. They have since held on to their gains.